After Raymond James and Guggenheim gave Allogene Therapeutics (NASDAQ: ALLO) a Buy rating last month, the company received another Buy, this time from JMP Securities. Analyst Reni Benjamin reiterated a Buy rating on Allogene Therapeutics today and set a price target of $23.00. The company's shares closed last Thursday at $9.25, close to its 52-week low of $7.48. According to TipRanks.com, Benjamin 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.2% and a 32.5% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.
https://www.tipranks.com/news/blurbs/allogene-therapeutics-allo-received-its-third-buy-in-a-row-2?utm_source=advfn.com&utm_medium=referral